Engineered Cas9 Nucleases for Target Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CRISPR/Cas systems face challenges with off-target binding and cleavage, raising regulatory concerns for therapeutic applications.
Innovation Solution
Engineered RNA-guided nucleases, such as Staphylococcus pyogenes Cas9 (SPCas9) variants with specific amino acid substitutions, are developed to enhance target specificity by reducing off-target activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type Cas9 is used for genome editing, then on-target cleavage activity is achieved, but off-target binding and cleavage occur reducing precision
Solution Approach 1:
The patent applies parameter changes by introducing specific amino acid substitutions at positions D23, D1251, Y128, T67, N497, R661, Q695, and Q926 in the Cas9 protein sequence. These parameter changes in the protein structure modify the enzyme's binding properties to reduce off-target effects while preserving on-target activity. The substitutions alter chemical properties such as charge, hydrophobicity, and steric characteristics at key interfaces.
Solution Approach 2:
The invention applies local quality by making targeted amino acid substitutions at specific positions within the Cas9 protein rather than uniform modifications. Each substitution addresss local interactions at particular binding interfaces or structural domains, such as the PAM recognition site or guide RNA binding region, to enhance specificity without compromising overall function.
2Reliability
If amino acid substitutions are introduced to improve specificity, then off-target activity decreases, but on-target binding efficiency may be reduced
Solution Approach 1:
The patent optimizes the balance between specificity and efficiency by carefully selecting amino acid substitutions that modify binding parameters without excessive stringency. The substitutions at positions such as D23 and T67 adjust electrostatic and hydrophobic interactions to favor specific target recognition while maintaining sufficient binding affinity for productive cleavage at intended sites.
Solution Approach 2:
The invention applies partial action by introducing a limited number of strategic amino acid substitutions rather than comprehensive modifications. This selective approach makes minimal changes to the protein structure, preserving most wild-type functional characteristics while achieving the desired improvement in specificity through targeted local modifications.
Data Source
AI summary
The present disclosure relates to Cas9 nuclease variants and methods of producing and using such variants.